Maury Raycroft
Stock Analyst at Jefferies
(0.56)
# 3,925
Out of 4,876 analysts
48
Total ratings
21.62%
Success rate
-16.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $3.15 | +11.11% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $7.40 | +616.22% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $2.56 | +212.50% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.54 | +454.63% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $2.66 | +163.16% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.31 | +358.02% | 1 | Nov 18, 2024 | |
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $3.99 | +326.07% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $5.01 | +279.24% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $2.42 | +519.83% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $17.63 | +121.21% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.74 | +709.72% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.46 | +1,475.34% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $6.90 | +2,726.09% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $9.36 | +17.52% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $22.65 | -73.51% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $16.08 | +366.42% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $322.83 | -28.14% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.35 | +152.87% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $9.10 | +196.70% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $2.45 | +104.08% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $12.54 | +282.78% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $5.80 | +520.69% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $4.72 | +2,124.58% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $47.49 | +262.18% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.35 | +1,900.00% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $4.35 | +5,187.36% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $9.56 | +339.33% | 3 | Nov 1, 2017 |
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $3.15
Upside: +11.11%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $7.40
Upside: +616.22%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.56
Upside: +212.50%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.54
Upside: +454.63%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.66
Upside: +163.16%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.31
Upside: +358.02%
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $3.99
Upside: +326.07%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $5.01
Upside: +279.24%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $2.42
Upside: +519.83%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $17.63
Upside: +121.21%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.74
Upside: +709.72%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.46
Upside: +1,475.34%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $6.90
Upside: +2,726.09%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $9.36
Upside: +17.52%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $22.65
Upside: -73.51%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $16.08
Upside: +366.42%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $322.83
Upside: -28.14%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $4.35
Upside: +152.87%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $9.10
Upside: +196.70%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $2.45
Upside: +104.08%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $12.54
Upside: +282.78%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $5.80
Upside: +520.69%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $4.72
Upside: +2,124.58%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $47.49
Upside: +262.18%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.35
Upside: +1,900.00%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $4.35
Upside: +5,187.36%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $9.56
Upside: +339.33%